FDG PET/CT in cancer: comparison of actual use with literature-based recommendations by unknown
ORIGINAL ARTICLE
FDG PET/CT in cancer: comparison of actual
use with literature-based recommendations
Henrik Petersen1 & Paw Christian Holdgaard2 & Poul Henning Madsen3 &
Lene Meldgaard Knudsen4 & Dorte Gad5 & Anders Eggert Gravergaard5 & Max Rohde6 &
Christian Godballe6 & Bodil Elisabeth Engelmann7 & Karsten Bech8 &
Dorte Teilmann-Jørgensen9 & Ole Mogensen10 & Jens Karstoft11 & Jørgen Johansen12 &
Janne Buck Christensen13 & Allan Johansen1 & Poul Flemming Høilund-Carlsen1 &
on behalf of the PET/CT Task Force of the Region of Southern Denmark
Received: 9 July 2015 /Accepted: 6 October 2015 /Published online: 30 October 2015
# The Author(s) 2015. This article is published with open access at Springerlink.com
Abstract
Purpose The Region of Southern Denmark (RSD), cov-
ering 1.2 of Denmark’s 5.6 million inhabitants,
established a task force to (1) retrieve literature evi-
dence for the clinical use of positron emission tomog-
raphy (PET)/CT and provide consequent recommenda-
tions and further to (2) compare the actual use of
PET/CT in the RSD with these recommendations. This
article summarizes the results.
Methods A Work Group appointed a professional Subgroup
which made Clinician Groups conduct literature reviews on
six selected cancers responsible for 5,768 (62.6 %) of 9,213
PET/CT scans in the RSD in 2012. Rapid Evidence Assess-
ment was applied, using the methodology of systematic re-
views with predefined limitations to search PubMed, Embase
and the Cochrane Library for articles published in English/
Danish/Swedish/Norwegian since 2002. PICO questions were
defined, data recorded and quality appraised and rated with
regard to strength and evidence level. Consequent recommen-
dations for applications of PET/CT were established. The ac-
tual use of PET/CTwas compared with these, where grades A
and B indicated Bestablished^ and Buseful^ and grades C and
D Bpotentially useful^ and Bnon-recommendable^ indications,
respectively.
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Results Of 11,729 citations, 1,729 were considered for re-
view, and 204 were included. The evidence suggested useful-
ness of PET/CT in lung, lymphoma, melanoma, head and
neck, and colorectal cancers, whereas evidence was sparse in
gynaecological cancers. The agreement between actual use of
PET/CT and literature-based recommendations was high in
the first five mentioned cancers in that 96.2 % of scans were
made for grade A or B indications versus only 22.2 % in
gynaecological cancers.
Conclusion Evidence-based usefulness was reported in five
of six selected cancers; evidence was sparse in the sixth,
gynaecological cancers. Actual use of PET/CT agreed well
with recommendations.
Keywords PET imaging . Rapid Evidence Assessment .
Recommendation . Lung cancer . Malignant lymphoma .
Malignant melanoma . Head and neck cancer . Colorectal
cancer . Gynaecological cancer
Introduction
Health expenditure is on the rise again after the economic
crisis and accounted for 9.3 % of the gross domestic product
on average across Organisation for Economic Co-operation
and Development (OECD) countries in 2012, well above
10 % in most Western European countries and much higher
(16.2 %) in the USA [1]. Almost two thirds of OECD coun-
tries have experienced absolute decreases in pharmaceutical
spending since 2009, whereas spending on hospital and out-
patient care increased in many countries in 2012 [1], one rea-
son being an increasing use of diagnostic tests including ad-
vanced diagnostic imaging [2]. Cancers figure among the
leading causes of morbidity and mortality worldwide with
14.1 million new cancer cases, 8.2 million cancer deaths and
32.6 million people living with cancer (within 5 years
of diagnosis) in 2012 worldwide, and the number of
new cases is expected to rise by about 70 % over the
next 2 decades [2, 3]. Corresponding numbers for Eu-
rope in 2012 were 3.7, 1.9 and 9.7 million and for the
USA 1.6, 0.9 and 4.8 million, respectively [3–5]. Can-
cer alone constitutes a major source of expenditure due
to expensive therapies and because multiple examina-
tions are used for several purposes, i.e. diagnostic/stag-
ing, response evaluation, detection of recurrence and
long-term follow-up [6–8]. In 2011 Denmark was
assigned the dubious honour of being the world’s cancer
capital with 226 new cases per 100,000 people [9], which rose
to 338 new cases per 100,000 in 2012, compared to 273 in the
UK, 284 in Germany, 296 in Canada and 318 in the USA
(Fig. 1) [10]. These circumstances place healthcare decision-
makers in a dilemma: Which diseases and treatments should
be given priority? It is a tricky problem with many stake-
holders, including patients, relatives, patient associations,
Fig. 1 Worldwide cancer incidence, 2012 estimates. Graded purple
shades indicate higher and graded blue shades indicate lower
incidences, while grey indicates less reliable data; see http://globocan.
iarc.fr. Accessed 7 Jul 2015
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medical specialties and healthcare personnel, not to mention
pharmaceutical and medical technologies. What can be done?
Numbers like these have created a massive demand for pos-
itron emission tomography (PET)/CT capacity in Denmark’s
five administrative regions, including the Region of Southern
Denmark (RSD) with its 1.2 of 5.6 million Danish inhabitants
(Fig. 2). As a consequence, in 2013 the RSD appointed aWork-
ing Group, commissioned to work in two successive stages. In
stage 1 to (1) identify and subdivide the evidence for the current
use of PET/CT and give recommendations based on evidence
strength and moreover to (2) compare the actual use of PET/CT
in the RSD with established recommendations. Additionally to
identify areas of future development and growth of PET/CT as
input to stage 2, which aims to provide recommendations for a
future strategy for the organization and use of PET/CT in the
RSD. Stage 1 results were reported in April 2014 (available in
Danish only at this link http://www.ouh.dk/wm442300) and
form the basis of this article.
Materials and methods
The work was organized at three levels: Working Group, Sub-
group, and six Clinician Groups. The members of these
groups are listed in the Appendix. The analysis should con-
centrate on clinically important patient-related outcomes in
conjunction with relevant alternative examination modalities
meaning that it should focus on studies in which PET/CT
contributed to clinical endpoints like survival, change of treat-
ment, etc. and exclude reports focusing exclusively on diag-
nostic accuracy. To ensure that the work could be completed
within a reasonable time, it was decided to focus on six cancer
areas, which by volume were the largest groups examined by
PET/CT in 2012 at the two PET/CT centres in the RSD. The
Working Group was chaired by the regional executive of
healthcare in the RSD and comprised 19 further members
representing four major hospitals of the region (Fig. 2). Each
of these hospitals was represented by a hospital manager, head
physicians and consultants in nuclear medicine, radiology and
selected clinical specialties. Five members were assigned to a
Subgroup comprising specialists in nuclear medicine, radiol-
ogy and a clinical specialty, which together with a project
coordinator was tasked to implement stage 1. For the literature
review, the Subgroup suggested six Clinician Groups, one for
each of six selected cancers that it was decided to focus upon,
namely (1) lung, (2) (malignant) lymphoma, (3) (malignant)
melanoma, (4) head and neck, (5) colorectal and (6)
gynaecological cancer. The six Clinician Groups consisted
typically of a contact person, i.e. a chief physician or professor
of the relevant specialty, and a clinical consultant, who was
exempted from ordinary service to perform the evidence re-
view. Thus, the analysis of available evidence was carried out
Fig. 2 a The five regions of Denmark with a large insert (Denmark’s
location in Europe) and a small insert (the Danish island of Bornholm
located in the Baltic Sea). The RSD (Syddanmark on the map) connects
Denmark with Germany (not shown) south of the Jutland Peninsula. The
red dots surrounded by blue circles represent the four main hospitals of
the region. b The number and placement of PET/CTscanners in Denmark
in 2007. c The number and placement of PET/CTscanners in Denmark at
the end of 2014
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by trained clinicians, all of whom were users of PET/CT. The
Subgroup supervised the work, compiled and prepared the
final report.
Literature review, level of evidence and consequent
recommendations
Due to a short time line (terms of reference for the Working
Group by 13May 2013, first meeting 27 June, Subgroup tasks
by 9 September, Clinician Groups established 1 November
and final stage 1 report 19 May 2014), the literature review
was undertaken as a Rapid Evidence Assessment (REA) and
did not include references published after April 2014. REAs
provide a balanced assessment of what is already known about
an issue, Bby using systematic review methods to search and
critically appraise existing research. They aim to be rigorous
and explicit in method and thus systematic but make conces-
sions to the breadth or depth of the process by limiting partic-
ular aspects of the systematic review process^ [11]. This was
achieved by formulating specific questions guiding the review
which need to be further limited if the question is broad; by
using results of existing reviews to find primary studies; and
by extracting primarily results and key data for simple quality
assessment to conduct simple quality appraisal of studies. To
ensure standardization, the searches were designed and carried
out by the Medical Research Library of Odense University
Hospital. They were confined to PubMed, Embase and the
Cochrane Library, but were not limited as such. The extent
of the review was adapted to each selected area. Two searches
were carried out for each selected area: one for systematic
reviews and meta-analyses only and another including all ar-
ticles excluding only conference papers and books (Embase).
Only articles in English, Danish, Swedish or Norwegian pub-
lished since 2002 were included, since publications on PET/
CT, in contrast to PET alone, were not available before then.
Search terms (MeSH and free text) were suggested by the
library and accepted by the Subgroup and Clinician Groups.
A total of 53 search terms were used for PET/CTand the most
common PET tracer, 18F-fluorodeoxyglucose (FDG), and ad-
ditional 887 terms were used for the six cancer areas. Only
studies about PET/CT (not PET/MRI or PET alone) were in-
cluded, with the exception that some reviews and meta-
analyses also included PET alone studies. The title and ab-
stract of each study were reviewed by the relevant Clinician
Group and studies focusing exclusively on diagnostic accura-
cy (sensitivity and specificity) were not included. In addition,
criteria for outcome, comparator and possible patient courses
were applied as determined by the Clinician Groups, which
made additional limitations where relevant. In accordance
with REA rules, the Clinical Groups were free to include/
exclude based on the following criteria: (1) the methodologi-
cal quality of the study being considered, (2) the relevance of
that research design for answering the REA question and (3)
the relevance of the study focus for answering the REA ques-
tion. A filled out template defining PICO questions for each
cancer area was used as guidance for the literature search and
for sorting. PICO is a widely used critical appraisal tool and an
acronym for population (e.g. patients with lung cancer), inter-
vention (e.g. PET/CT), comparison (for the modality of com-
parison, e.g. CT alone) and outcome (e.g. relapse) [12].
Likewise, standardized evidence tables were filled out for
each included article to record information on the area of re-
search (e.g. lung cancer and described patient courses), source
(authors, affiliations, journal, year of publication, etc., and
number of references), objective, study design, study period,
population and number of patients, results and comments.
Next, the evidence level of each article was rated according
to a Danish version [13] of a standardized system devised by
the Oxford Centre for Evidence-Based Medicine designating
various levels of evidence to articles. At the time the project
was commissioned, this methodology was the one endorsed
by the Danish Health and Medicines Authority, in particular
the Blevels of evidence and grades of recommendations^.
From January 2014 onwards the Danish authority recom-
mends instead the GRADE system [14] for all national clinical
guidelines. The methodology in our report follows the same
transparent and structured approach as recommended by
GRADE, only with adjustments regarding the breadth and
depth of the literature. The highest levels (1a, 1b, 1c) denote
systematic reviews/meta-analyses, randomized controlled tri-
als and absolute effect studies, respectively, whereas the low-
est level (5) indicates expert opinion without explicit critical
appraisal, or based on physiology, bench research or Bfirst
principles^ [15]. Thereafter, the evidence levels of all studies
answering a distinct PICO question were used to provide
graded recommendations for the use of PET/CT. Grade A
recommendation was used for consistent level 1 studies, B
for consistent level 2 or 3 studies or extrapolations from level
1 studies, C for level 4 studies or extrapolations from level 2 or
3 studies and D for level 5 evidence or troublingly inconsistent
or inconclusive studies of any level. BExtrapolations^ were
where data were used in a situation that had potentially clini-
cally important differences than the original study situation
[15]. Finally, based on the literature review, level of evidence
and recommendation grade, each Clinical Group prepared a
summary with a conclusion and their recommendation for the
use of PET/CT. This was filled into another standardized re-
port form including also their estimates for further develop-
ments in the use of PET/CT within each particular area.
PET/CTactivity in the RSD and its agreement
with recommendations
Using this material and colour codes for the potential clinical
applications of PET/CT in cancer, i.e. diagnosis, staging, re-
sponse evaluation, targeting of radiation therapy, disease
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control and recurrence detection, the Subgroup compared the
results of the review and the Clinician Groups’ recommenda-
tions with the actual use of PET/CT in the RSD according to
2012 statistics. For this comparison, the three gynaecological
cancers (ovary, cervical and uterine) were handled separately.
Prediction of future development and growth
The report forms of the Clinician Groups including estimates
for further developments in the use of PET/CT served as the
basis for estimates prepared by the Subgroup for development
and growth in PET/CT in years to come.
Results
Literature survey, level of evidence and consequent
recommendations
Of 11,729 retrieved citations, 1,729 were considered for review,
and 204 were included for the purposes of this survey, the sum-
marized results of which are given in Supplementary Tables 1–6
in Online Resource 1. The amount and quality of articles within
each cancer type varied considerably and was in general more
comprehensive and of higher quality within lung, haematological
and head and neck cancer than colorectal cancer, malignant mel-
anoma and gynaecological cancers, where documentation was
often heterogeneous, sporadic or lacking. The following was of
note within the six cancer groups (for details see also Supple-
mentary Tables 1–6 in Online Resource 1).
Lung cancer
The use of PET/CT in the work-up of solitary pulmonary nod-
ules may substantially reduce the number of invasive examina-
tions [15–20] (Fig. 3). PET/CT prior to intended curative ther-
apy may lower the number of futile operations by about 20 %
[21]. A negative PET/CT in patients with suspected adrenal
metastases may eliminate the need for biopsy [22].
Malignant lymphoma
There was good evidence to recommend PET/CT for staging,
response and end evaluation of patients with Hodgkin’s and
diffuse large B-cell lymphoma [23–28]. Considerable benefi-
cial effect has been reported in the shape of change in stage and
therapy and with regard to prediction of progression-free sur-
vival [29, 30]. PET/CT helps to identify patients not in need of
additional radiotherapy and is recommended before high-dose
chemotherapy with stem cell support in patients with relapse, as
all studies showed shorter progression-free survival with PET/
CT positivity [31–34]. Thus, PET/CTmay play a future role for
the selection of patients for this kind of therapy.
Malignant melanoma
It is recommended that all patients found to have metastatic
malignant melanoma (stage 3) according to sentinel node di-
agnostics are offered additional staging with PET/CT, as this
is the most sensitive way of diagnosing distant metastases
[35–37]. When examining patients with high-risk metastatic
melanoma (stages 3–4), there is literature consensus that PET/
CT is the best modality to identify melanoma metastases
[36–40]. PET/CT can detect unrecognized metastases, which
may lead to altered management of 10–19 % of patients
[40–43].
Head and neck cancer
Studies indicate that PET/CT should be recommended in the
diagnostic work-up and staging [44, 45]. In unknown pri-
maries in the head and neck region, PET/CT identifies at least
30 % of primary tumours not detected by conventional means
Fig. 3 A scan showing one of the powers of PET/CT: In a patient with an
isolated tumour in the upper right lobe of the lung, PET/CT revealed a
potential lymph node metastasis just above the centre of the right
diaphragmatic dome and an unknown lesion in the thyroid gland, not
detected during work-up or by other imaging, but verified by biopsy
following PET/CT
Eur J Nucl Med Mol Imaging (2016) 43:695–706 699
[46, 47]. PET/CT optimizes restaging of patients with recur-
rence [48, 49].
Colorectal cancer
PET/CT is of benefit for the decision of surgery for liver
metastases if CTor MRI is equivocal and/or to rule out distant
metastases or secondary cancers obviating curative interven-
tion [50, 51]. PET/CT can be of use in suspected recurrence,
when CT is negative [52, 53], and PET/CT is recommended as
first choice in patients with increased suspicion of recurrence
[54, 55].
Gynaecological cancers
PET/CT is recommended for response evaluation in cer-
vical cancer, being superior for evaluation of treatment
efficacy, and is a predictor of event-free and overall
survival [56, 57]. On suspicion of advanced uterine can-
cer PET/CT is recommended for the choice between
surgical or systemic treatment [58]. Studies in uterine
cancer have low levels of evidence, but do show power
of PET/CT for the detection of local relapse and distant
metastases, as this may cause a change in management
in 22–35 % of cases [59, 60]. PET/CT is recommended
in patients with suspected recurrence of ovarian cancer
due to elevated cancer antigen 125, but with negative
CT and MRI [61]. Finally, PET/CT is considered the
most accurate method for restaging from assessment of
spread to the peritoneum, lymph nodes and local relapse
[62, 63].
PET/CTactivity in the RSD and its agreement
with recommendations
As shown by colour coding in Table 1, there was a clear and
purposeful relationship in that the vast majority of PET/ CT
scans were performed on indications that have good evidence
(green and yellow markings), while only a small proportion
was performed on indications of low or lacking evidence (or-
ange and purple markings).
Prediction of future development and growth
FDG will remain the dominant tracer, but new tracers are
needed in the routine, for specialized functions, and for devel-
opment of molecular imaging in general [64–67]. Solid-state
PET detectors imply improved sensitivity, detection of smaller
lesions and higher patient throughput [68]. PET/CT will be
used in more cancers and often with more than one to two
scans per patient [69], and PET/CT will play a role in infec-
tions of unknown origin [70], inflammation [71, 72], neuro-
logical disorders [67, 73–75] and cardiovascular disease,
probably replacing myocardial scintigraphy [76–78].
Discussion
Principal findings
When comparing the actual use of PET/CT with the recom-
mendations derived from the review there was a high agree-
ment except in gynaecological cancer. Thus, when summariz-
ing the percentages of scans actually used for each purpose in
Table 1 PET/CT scans in the RSD 2012
CANCER No. in 
2012 
% Known Suspected Not 
stated 







Small and non-small cell 2407 26 470 1924 13 62% 22% 3% 0% 3% 10% 
Haematological 
Malignant lymphoma 1150 12 950 180 20 18% 19% 36% 1% 9% 17% 
Skin 
Malignant melanoma 383 4 369 12 2  8% 30% 4% 0% 13% 45% 
Head and neck 
Planocellulary cancers 344 4 271 69 4 31% 24% 5% 8% 3% 29% 
Gastrointestinal 
Colerectal 827 9     0% 15% 0% 2% 22% 61% 
Gynaecologic 
26322114053yravO 59% 15% 7% 0% 1% 18% 
Cervical 241 3 204 33 4 18% 33% 17% 0% 11% 21% 
21135166eniretU 28% 30% 6% 0% 4% 32% 
No. of PET/CT scans:
Total, survey 5768 Number of scans in the six selected cancer types (lung, haematological, skin, head and neck, gastrointestinal, gynaecologic)-
Total, in RDS 2012 9213 Total number of scans (the number above plus scans for other purposes)
R e c o m m e n d a t i o n s :
A Established clinical indication supported by experience and literature. 
B Useful clinical indication. Less literature, more research needed. Less pronounced advantages compared to conventional imaging than in A. 
C Potentially useful indication. Minimal experience and literature. Much more research is needed. 
D Of little value, not recommendable as standard procedure. Limited accuracy, cost-effectiveness or lacking clinical impact, occasionally useful.
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each type of cancer (see horizontal lines in Table 1), the sum of
percentages that was in agreement with established (green
colour code) or useful (yellow colour code) indications were
(in rounded-off numbers) 97 % in lung, 99 % in lymphoma,
88 % in melanoma, 87 % in head and neck and 98 % in
colorectal cancer. In these five cancers, only 3 % of scans
(in lung patients) were with an indication of limited usefulness
(purple colour code), whereas in 8 % (in head and neck pa-
tients) the indication was Bpotentially useful, albeit with min-
imal documentation^ (orange colour code). The remaining 0–
12 % of indications in each of these five cancers were not
covered in this review. In gynaecological cancers, the picture
was less uniform. In uterine cancer, 58 % of a low number of
scans were used for an established indication (green colour
code). In ovarian and cervical cancers, only 19 and 17 % of
scans had an established indication (green colour code),
whereas the remaining 81 and 83 %, respectively, were made
for a Bpotentially useful indication, albeit with minimal
documentation^ (orange colour code). In gynaecological
cancers, the remaining 0–6% of scans were made for indications
not covered in this review (Table 1). Continued development
and growth of PET/CTwas foreseen in all six cancer areas, and
in additional cancer types, in infections and inflammation, and
cardiovascular and neurological diseases.
Strengths and weaknesses
A major strength of this review with recommendations was
that it was undertaken by the clinical users and not experts in
nuclear medicine. In theory, the latter category might have an
interest in promoting PET/CT, while conversely recommen-
dations provided by clinicians might underestimate the use-
fulness of PET/CT, the more so, the less the clinicians knew
about PET/CT. Apparently, this type of bias was not prevalent
as most clinical participants were experienced in the use of
PET/CT, and because the recommendations were based on
literature evidence and not on user experience.
Unfortunately, the review did not include all cancers and
non-malignant diseases. To cover all potential applications of
PET/CT was impossible if the review should have sufficient
depth and quality within the limited time frame provided by
the healthcare decision-makers. The chosen six cancer types
accounted for almost two thirds of actually performed PET/
CTscans in the RSD in 2012, i.e. 5,768 of a total of 9,213.We
chose to use the method of REA allowing us to catch just
about all existing literature within each area before predefined
restrictions were used to reduce the number of articles to make
the task manageable in due time.
Other studies
We are not aware of similar reviews undertaken by the users.
There are multiple studies on the accuracy of PET and PET/
CT by specialists in radiology and/or nuclear medicine. The
most comprehensive one was a tabulation of literature on
FDG PET in oncology, cardiology and neurology published
before July 2000 and prepared from documents submitted to
the Health and Care Financing Administration (HCFA) in the
USA [today’s Centers for Medicare and Medicaid Services
(CMS)] in 2000 to request expandedMedicare reimbursement
for FDG PET [79]. It showed an average estimated FDG PET
sensitivity and specificity across all oncology applications at
84% (based on 18,402 patient studies) and 88% (based on 14,
264 patient studies), respectively, and an average estimated
management change across all applications of 30 % (based
on 5,062 patient studies). The average accuracies for the six
cancer areas of our review across all applications ranged then
between 87 and 94 %, while the change in management aver-
aged 25 % (range 5–37 %). This extensive type of survey was
never repeated. The number of randomized trials on FDG
PET/CT remains low [80], and emerging systematic reviews
are inherently limited to answer only a single or a few key
questions [81]. Two Danish studies, based on 743 PET and 6,
056 PET/CT scans, reported a change in management with
PET and PET/CT in 43 and 36 % of cases, respectively [82,
83].
Clinical PETcame to life in 1976 [84], but its use remained
experimental for a quarter of a century. However, when in
1999 the HCFA announced coverage for FDG PET in solitary
lung nodules it was the starting signal of an almost explosive
growth which was further boosted with the appearance of
PET/CT scanners in 2001 and the CMS giving coverage in
2005 for a number of applications in several cancers, provided
the cases were registered in a National Oncology PET Regis-
try. Early reports from this registry estimated that PET/CT
caused a change in management in about one third of cases
[85, 86]. A major health technology assessment in the UK,
based on literature up to August 2005 covering mainly stand-
alone PET, aimed to assess the clinical effectiveness of FDG
PET in breast, colorectal, head and neck, lung, lymphoma,
melanoma, oesophageal and thyroid cancers [54]. Based on
6 systematic reviews and 158 primary studies, the strongest
evidence of the clinical usefulness was found in lung cancer,
for restaging Hodgkin’s lymphoma and staging/restaging co-
lorectal cancer. It was concluded that clinical audit and further
research was needed, but also that the PET clinical effective-
ness could be extrapolated to cover PET/CT as the latter ap-
peared to be slightly more accurate. Since then, two or more
new generations of PET/CT scanners have reached the market
and visual comparison alone can verify significant improve-
ments. However, the literature on the clinical benefit of PET/
CT is still limited. Randomized studies on clinical outcome
are in short demand and should preferably focus on patient-
relevant outcomes and cost-effectiveness [80, 81, 87]. Precise
mapping of individual patient courses is required for docu-
mentation of clinical benefit. This is often not possible in the
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USA and Southern European countries because of frequent
private clinics and practices. The situation is different in
Northern Europe with countries like Denmark, because access
to healthcare is free, the private sector is minimal and personal
ID and nationwide databases make patient follow-up almost
100% complete over time. The PET/CT infrastructure in Den-
mark is well established with rates of PET/CT scanners per
million inhabitants exceeding the European average [42] and
nuclear medicine centres within easy reach for most inhabi-
tants. Therefore, multicentre studies from these countries may
be the way to go to document the clinical effects of PET/CT
and PET/MRI.
Meaning of the study: possible explanations
and implications for clinicians and policymakers
This review, other studies and market analyses foresee that
PET/CTwill continue to develop significantly for years to come
in cancer and other diseases. The relative lack of documentation
is not a phenomenon confined to PET/CT. It applies also to
conventional imaging modalities, the use of which has been
steadily increasing until recently [88, 89]. The molecular prin-
ciple is unique and allows detection and monitoring of disease
and its response to therapy often much earlier than what is
possible with conventional imaging [67, 73, 90]. It is, therefore,
not surprising that clinicians and healthcare policymakers are
interested in this technology, its options and to what extent its
use will benefit patients in an affordable way.
Unanswered questions and future research
Do we need PET/CT or not? The concept of PET/CT is fun-
damentally different from that of traditional imaging with X-
ray, CTorMRI. They display structure and allow for measure-
ment of some physiological parameters. PET/CT can display
and quantify molecular processes in the entire body in a single
noninvasive examination with a molecular sensitivity much
higher than with conventional modalities [91]. Problems with
limited spatial resolution of PET were obviated and an in-
creased diagnostic accuracy obtained with the introduction
of PET/CT. However, diagnostic accuracy alone does not suf-
fice unless consequent downstream changes in patient man-
agement are translated into improved patient outcome to a
degree justifying purchase of additional scanners. The present
literature reviews and the consequent recommendations were
prepared by users rather than providers of PET/CT, which
other things being equal may have a greater impact on admin-
istrators’ and policymakers’ decisions than those of imaging
professionals. However, much still needs to be done to prevent
PET/CT from becoming just another excellent examination
instead of another’s preferred successor. The next step in our
local process is to use this review to suggest strategies for the
future organization and use of PET/CT in the RSD. These
suggestions will be published elsewhere.
Conclusion
This review suggested evidence-based usefulness in five of
six selected cancer types and sparse documentation in the
sixth type, gynaecological cancers. Actual clinical use of
PET/CT agreed well with evidence-based recommendations.
Development and growthwas foreseen inmany cancers and in
other major types of disease. This calls for concomitant qual-
ity assessment strategies to ensure proper clinical
implementation.
Epilogue
This article is neither a typical original paper, nor a typical
review. It is basically a summary of a commissioned work
and its key results: The owners of the hospitals in the RSD
wanted to know if there is sufficient evidence for the clinical
use of PET/CT, and if its actual use in the RSD agrees with the
available evidence. Users and not providers of PET/CTcarried
out the reviews and established the recommendations for com-
parison with the actual use of PET/CT in the region and, thus,
their work and the comparison could not be influenced by
radiologists and nuclear medicine specialists among the au-
thor team.
This type of report does not leave much room for additional
reflections on the PET/CT method and its role in cancer man-
agement and, therefore, an epilogue may be an appropriate
way to state a few professional views. FDG is the by far most
common PET tracer being used worldwide in more than 90 %
of cancers in clinical practice, based on a longstanding vali-
dation over the past few decades [67, 92]. PET/CT is changing
the paradigm in cancer management from simple lesion mea-
surement to lesion and whole-body characterization
supporting a new era in personalized cancer therapy [93].
Despite an array of new PET tracers, the clinical recognition
of these is slow in coming, and not only due to lengthy, cum-
bersome and expensive test procedures. For example, tracers
characterizing cell proliferation, hypoxia or angiogenesis are
scientifically highly interesting in providing new insight into
disease mechanisms, but in the clinical setting they appear to
be redundant to FDG, because the cumulative effects of the
underlying biology are reflected by the levels of glucose me-
tabolism, which is what is depicted by FDG PET (Kwee T,
Gholami S,Werner TJ, Alavi A, Høilund-Carlsen PF. FDG, as
a single imaging agent in assessing cancer, portrays the ongo-
ing biological phenomena in many domains; do we need ad-
ditional tracers for clinical purposes?; submitted). Studies
should address challenges with using the standardized uptake
values to discriminate malignant from benign lesions and
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follow changes over time during various therapeutic regimens.
With novel quantitative techniques including partial volume
correction and global disease assessment, FDG PET/CT has
the potential to become an even more powerful modality in
day-to-day practice of oncology. To demonstrate convincingly
the clinical utility of PET/CT there is a dire need of large,
multicentre and randomized studies, the number of which is
surprisingly low [80]. In times of budget constraint, cost-
effectiveness aspects of using PET/CT [87] should also be
considered to ensure a balanced basis for decisions about the
position of PET/CT in tomorrow’s healthcare.
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